Earlier this week, BeiGene, with offices in Beijing, China and Cambridge, Massachusetts, announced results from its pivotal Phase III trial of its anti-PD-1 antibody tislelizumab in combination with two chemotherapy agents in squamous non-small cell lung cancer (NSCLC). The drug, a checkpoint inhibitor, met the primary endpoint of improved progression-free survival (PFS) at the planned interim analysis. If tislelizumab is approved, it sets the company on a collision course with the dominant player in the checkpoint inhibitor market, Merck and it’s Keytruda (pembrolizumab).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,